drugset / Trial / NCT01495169

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

NCT01495169

Phase 1 Completed 33 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication

Timeline

Start
2011-10
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 6 mg Oral
Subject Iloperidone Small molecule 12 mg Oral
Subject Iloperidone Small molecule 16 mg Oral
Subject Iloperidone Small molecule 20 mg Oral
Subject Iloperidone Small molecule 24 mg Oral

Indications

No indication recorded.